Suppr超能文献

当代关于结直肠癌不可切除肝转移行肝移植的系统评价。

A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer.

机构信息

Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, Tennessee.

出版信息

Cancer. 2022 Jun 15;128(12):2243-2257. doi: 10.1002/cncr.34170. Epub 2022 Mar 14.

Abstract

The 5-year overall survival rate of a patient with unresectable metastatic colorectal cancer is poor at approximately 14%. Similarly, historical data on liver transplantation (LT) in those with colorectal liver metastases (CRLM) showed poor outcomes, with 5-year survival rates between 12% and 21%. More recently, limited data have shown improved outcomes in select patients with 5-year overall survival rates of approximately 60%. Despite these reported survival improvements, there is no significant improvement in disease-free survival. Given the uncertain benefit with this therapeutic approach and a renewed investigational interest, we aimed to conduct a contemporary systematic review on LT for CRLM. A systematic review of the literature was performed according to the preferred reporting items for systematic reviews and meta-analysis statement. English articles reporting on data regarding LT for CRLM were identified through the MEDLINE (via PubMed), Cochrane Library, and ClinicalTrials.gov databases (last search date: December 16th, 2021) by 2 researchers independently. A total of 58 studies (45 published and 13 ongoing) were included. Although early retrospective studies suggest the possibility that some carefully selected patients may benefit from LT, there is minimal prospective data on the topic and LT remains exploratory in the setting of CRLM. Additionally, several other challenges, such as the limited availability of deceased donor organs and defining appropriate selection criteria, remain when considering the implementation of LT for these patients. Further evidence from ongoing prospective trials is needed to determine if and to what extent there is a role for LT in patients with surgically unresectable CRLM.

摘要

无法切除的转移性结直肠癌患者的 5 年总生存率较差,约为 14%。同样,结直肠癌肝转移患者肝移植(LT)的历史数据显示预后较差,5 年生存率在 12%至 21%之间。最近,有限的数据表明,在选择的患者中,5 年总生存率约为 60%,结果有所改善。尽管这些报道的生存率有所提高,但无疾病生存率并无显著改善。鉴于这种治疗方法的获益不确定,并且重新引起了研究兴趣,我们旨在对结直肠癌肝转移患者的 LT 进行当代系统评价。根据系统评价和荟萃分析报告的首选项目进行了文献系统评价。通过 2 名研究人员独立通过 MEDLINE(通过 PubMed)、Cochrane 图书馆和 ClinicalTrials.gov 数据库(最后搜索日期:2021 年 12 月 16 日)检索报告结直肠癌肝转移患者 LT 数据的英文文章。共纳入 58 项研究(45 项已发表,13 项正在进行)。尽管早期的回顾性研究表明,一些经过精心挑选的患者可能从 LT 中获益,但关于该主题的前瞻性数据很少,LT 在结直肠癌肝转移的背景下仍处于探索阶段。此外,在考虑为这些患者实施 LT 时,还存在其他一些挑战,例如供体器官的有限可用性和定义适当的选择标准。需要正在进行的前瞻性试验的进一步证据来确定 LT 在手术不可切除的结直肠癌肝转移患者中的作用是否以及在何种程度上存在。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba1/9311758/4cab50613da8/CNCR-128-2243-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验